𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of chlorozotocin in metastatic sarcomas

✍ Scribed by ;Presant, Cary A. ;Bartolucci, Alfred A.

Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
187 KB
Volume
12
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-nine evaluable patients with anthracycline-resistant metastatic bone or soft tissue sarcomas were treated with chlorozotocin, 150 mg/m2 every 6 weeks. Four patients (14%) achieved partial responses. The most severe toxicity was usually thrombocytopenia (which occurred in 31% of patients). Chlorozotocin has only minimal activity in drug-resistant metastatic sarcomas.

πŸ“œ SIMILAR VOLUMES

Phase II trial of gemcitabine in advance
Phase II trial of gemcitabine in advanced sarcomas
✍ Scott Okuno; John Edmonson; Michelle Mahoney; Jan C. Buckner; Stephen Frytak; Ev πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 63 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Care for patients with advanced sarcomas is mainly palliative. Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine that has shown antitumor activity in several tumors. The aim of the current study was to determine the clinical activity of gemcitabine i

A phase II trial of temozolomide in pati
A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma
✍ Susan M. Talbot; Mary Louise Keohan; Mary Hesdorffer; Russell Orrico; Emilia Bag πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 3 views

## Abstract ## BACKGROUND The objective of this study was to assess the efficacy and toxicity of the imidazotetrazine derivative temozolomide for patients with unresectable or metastatic soft tissue sarcoma. ## METHODS Twenty‐five of 26 patients were eligible and assessable for toxicity and resp